Teladoc Mergers and Acquisitions Presentation Deck
Endnotes
Page 21
1. Example synergy calculation approach includes cross-sell of Livongo products into
Teladoc only and does not account for the full ~55% of 2025 revenue synergy value
attributed to the overall cross-sell opportunity described on page 20. Does not include
cross-sell of Teladoc products into Livongo customers, does not include expansion of
Livongo into Small and Medium Businesses, Managed Medicaid, and Hospitals & Heath
Systems, does not include development and distribution of an integrated Behavioral
Health product across both customer bases
Page 23
1. Example synergy calculation approach includes referrals from Teladoc to Livongo
products only and does not account for the full ~25% of 2025 revenue synergy
attributed to the overall referral opportunity described on page 20. Does not include
referral of Livongo users to Teladoc products
Page 36
1. Teladoc financial projections for the year ending December 31, 2020 reflects Teladoc's
acquisition of InTouch Health Technologies, Inc., which was completed on July 1, 2020.
2. Adjusted gross profit is a non-GAAP financial measure and consists of total revenue
minus total cost of revenue (exclusive of depreciation and amortization shown
separately).
3. Adjusted EBITDA is a non-GAAP financial measure and consists of net loss before
interest, foreign exchange gain or loss, taxes, loss on extinguishment of debt,
depreciation, amortization, stock-based compensation, gain on sale and acquisition and
integration related costs.
4. Non-GAAP gross profit is a non-GAAP financial measure and consists of gross profit,
excluding (i) stock-based compensation expense, (ii) amortization of intangible assets,
and (iii) employer payroll taxes on stock-based compensation.
Livongo®
Teladoc
HEALTH
5. Adjusted EBITDA is a non-GAAP financial measure and consists of net loss adjusted to
exclude (i) depreciation and amortization, (ii) amortization of intangible assets, (iii)
stock-based compensation expense, (iv) employer payroll taxes on stock-based
compensation, (v) acquisition-related expenses, (vi) change in fair value of contingent
consideration, (vii) other income, net and (viii) provision for (benefit from) income taxes.
O Teladoc Health, Inc. All rights reserved.
34View entire presentation